A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

7041Background: In vitro studies showed that ofatumumab (O), a type I human antibody that targets a different CD20 epitope compared to rituximab, induces more potent antibody-dependent and compleme...